INTRODUCTION
============

Cellular metabolism, which consists of the concerted actions of many thousands of genes, proteins, and metabolites, refers to the complex chemical reactions that occur in living cells. Generally, these reactions can be divided into those supporting catabolic metabolism or anabolic metabolism. Catabolic metabolism, which includes glucose transport, fatty acid β-oxidation and other processes, converts complex molecules to simpler molecules. In contrast, anabolic metabolism, which includes lipogenesis, gluconeogenesis and other processes, converts simple precursor molecules into more complex biomolecules such as proteins and other polymers. The reactants and products of these chemical reactions are known as metabolites. An imbalance of metabolic functions is associated with the pathogenesis of metabolic diseases ([@b5-ksmcb-42-292]; [@b7-ksmcb-42-292]; [@b28-ksmcb-42-292]; [@b75-ksmcb-42-292]). Metabolic diseases include cardiovascular disease (CVD), type 2 diabetes (DM2), stroke, chronic kidney disease (CKD) and cancer. These diseases are caused by complicated conditions such as insulin resistance, obesity, dyslipidemia, hypertension and hyperglycemia ([@b1-ksmcb-42-292]; [@b26-ksmcb-42-292]). The pathogenesis of metabolic disease is related to altered metabolism and immune responses, which can lead to activation and infiltration of immune cells into metabolic tissues, such as liver, adipose tissue and skeletal muscle; and chronic low-grade activation of inflammatory pathways in both stromal and immune components. These events may be followed by the activation of stress kinases, such as c-Jun N-terminal kinase (JNK); and the mammalian target of rapamycin complex 1 (mTORC1), activation of which negatively affects the signaling of metabolic hormones such as insulin, leading to dysregulated glucose and lipid homeostasis ([@b4-ksmcb-42-292]; [@b31-ksmcb-42-292]; [@b51-ksmcb-42-292]; [@b78-ksmcb-42-292]). Altered cellular metabolism is a hallmark of cancer, and contributes to the conversion to malignancy and the initiation, growth and maintenance of tumors ([@b28-ksmcb-42-292]). Metabolites in tumors can have profound effects on both cancer cells and immune system cells. For example, adenosine is known to enhance tumor progression, whereas this compound inhibits proinflammatory responses ([@b64-ksmcb-42-292]).

Immunometabolism refers to an emerging research field at the interface of metabolism and the innate immune system ([@b52-ksmcb-42-292]). In 1966, the first observation of immunometabolism was the infiltration of macrophages into adipose tissue in obese mice ([@b29-ksmcb-42-292]). Specifically, the term immunometabolism describes two major processes: (I) the progression of non-immune pathologies, such as obesity, can result in the mobilization of innate and adaptive immune systems; (II) secondly, the dysbalance of internal metabolites can influence the immune response of lymphocytes and other leukocytes. Thus, metabolism and immunity have been broadly linked throughout evolution ([@b31-ksmcb-42-292]; [@b66-ksmcb-42-292]). Many studies have implicated immunometabolism during the development of metabolic disease. For example, the conditioned medium from macrophages incubated with LPS can induce resistance to insulin-induced glucose uptake and lipoprotein lipase expression in adipocytes ([@b63-ksmcb-42-292]). Adipose tissue-derived TNF-α contributes to type 2 diabetes in obese mice ([@b74-ksmcb-42-292]). In addition, various signaling pathways have been linked to glucose metabolism ([@b13-ksmcb-42-292]; [@b21-ksmcb-42-292]). Recently, it has been reported that adipose tissue-resident immune cells play an important role in tissue remodeling during weight gain and brown adipose tissue modulation ([@b48-ksmcb-42-292]; [@b77-ksmcb-42-292]). Therefore, the relationship between metabolic diseases and the innate immune response is closely related, such that immunometabolism can be a therapeutic target for metabolic diseases. On the other hand, the behavior of leukocytes and lymphocytes can be regulated by metabolism. Changes in CD8^+^ and CD4^+^ T cell populations have been associated with diabetes. In diabetic patients, CD8^+^ T cells were associated with impaired glycemic control and lipidemia in Type 1 diabetes ([@b46-ksmcb-42-292]), and CD4^+^ T cells were associated with progression of subclinical inflammation in Type 2 diabetes ([@b45-ksmcb-42-292]; [@b68-ksmcb-42-292]). In addition, B cells were associated with metabolic homeostasis. Specifically, B-1a lymphocytes can attenuate insulin resistance through IL-10 and IgM-dependent mechanisms ([@b69-ksmcb-42-292]). Furthermore, the polarization of macrophage is important for progression of obesity ([@b49-ksmcb-42-292]). M1 macrophages induce insulin resistance, whereas M2 macrophages protect against obesity-induced insulin resistance ([@b10-ksmcb-42-292]). Metformin has been commonly used to treat DM2 ([@b76-ksmcb-42-292]). Metformin enhances the insulin response and glucose transport through adenosine monophosphate-activated protein kinase (AMPK) activation ([@b67-ksmcb-42-292]). Also, metformin inhibits fatty acid synthesis, and increases β-oxidation in an AMPK-dependent manner ([@b83-ksmcb-42-292]). Beyond the modulation of glucose and lipid metabolism, metformin can exert anti-inflammatory functions ([@b8-ksmcb-42-292]; [@b14-ksmcb-42-292]; [@b41-ksmcb-42-292]). Metformin has been used to treat not only DM2 but also other metabolic diseases, such as CVD, non-alcoholic fatty liver disease (NAFLD) and cancer, in both an AMPK-dependent and -independent manner ([@b3-ksmcb-42-292]; [@b23-ksmcb-42-292]; [@b24-ksmcb-42-292]; [@b42-ksmcb-42-292]; [@b82-ksmcb-42-292]). Metformin, when administered at high doses (3000 mg/day) for treatment, can cause side effects such as gastrointestinal disturbances ([@b71-ksmcb-42-292]) and lactic acidosis ([@b16-ksmcb-42-292]).

Carbon monoxide (CO) is another molecule that can modulate metabolic responses. Endogenous CO is produced by the enzyme heme oxygenase-1 (HO-1) ([@b59-ksmcb-42-292]). CO has anti-inflammatory and antioxidant effects ([@b34-ksmcb-42-292]; [@b44-ksmcb-42-292]) and can confer cytoprotection in metabolic diseases *via* activation of the PERK pathway ([@b36-ksmcb-42-292]; [@b40-ksmcb-42-292]). CO-releasing molecules (CORMs), can be used as an alternative and potentially safer substitute for inhalation of gaseous CO ([@b55-ksmcb-42-292]). Furthermore, CO can have a cytoprotective effect at low concentrations ([@b59-ksmcb-42-292]). Metformin and CO have been shown to attenuate progression of metabolic diseases, obesity, DM2 and cancer, by various molecular pathways.

Therefore, further studies are needed to identify the differences between metformin and CO, and to determine if CO, which has a therapeutic effect at low concentrations, can compensate for the disadvantages of metformin, which can also incur side effects at high doses. Both metformin and CO continue to show potential for therapeutic application in metabolic diseases associated with immunometabolism, though further studies are needed.

ROLES OF METFORMIN IN IMMUNOMETABOLISM
======================================

Metformin is known as metabolic drug that is extensively prescribed for DM2 due to its ability to enhance insulin sensitivity. Numerous studies have demonstrated that metformin regulates glucose and lipid metabolism ([@b9-ksmcb-42-292]; [@b12-ksmcb-42-292]; [@b22-ksmcb-42-292]; [@b84-ksmcb-42-292]). Also, metformin has been shown to decrease various proinflammatory markers, including soluble intercellular adhesion molecule, vascular cell adhesion molecule 1, macrophage migration inhibitory factor and C-reactive protein ([@b8-ksmcb-42-292]; [@b14-ksmcb-42-292]). Metformin also influences the behavior of immune cells in response to metabolic mediators. For example, metformin can enhance B cell responses through a reduction in B cell-intrinsic inflammation in individuals with obesity and DM2 ([@b18-ksmcb-42-292]). Metformin was also shown to regulate the immune response by alteration of macrophage polarization and T cell infiltration in a zebrafish model of NAFLD-associated hepatocellular carcinoma ([@b15-ksmcb-42-292]). Furthermore, it has been reported that metformin can exert anti-inflammatory effects, which are related to an alteration in macrophage polarization to the M2 phenotype through activation of AMPK in a HFD-induced model of obesity, and in palmitate-stimulated macrophage in vitro ([@b35-ksmcb-42-292]). The intracellular target of metformin is the mitochondria, where metformin transiently inhibits complex I of the mitochondrial ETC, which results in a decline in energy charge. This inhibition of complex I induces a mild elevation in mitochondrial reactive oxygen species (mtROS) ([@b42-ksmcb-42-292]), a decrease in ATP production and an increase in AMP levels which drive the activation of AMPK ([@b83-ksmcb-42-292])([Fig. 1](#f1-ksmcb-42-292){ref-type="fig"}).

AMPK acts as an energy and nutrient sensor and coordinates an integrated signaling network that constitutes metabolic and growth pathways. Metformin-induced AMPK activation exhibits enhancement of glucose transport ([@b27-ksmcb-42-292]) and inhibits gluconeogenic gene expression *via* the cAMP-response element-binding protein (CREB) and the CREB-regulated transcription coactivator 2 (CRTC2) ([@b47-ksmcb-42-292])([Fig. 1](#f1-ksmcb-42-292){ref-type="fig"}). AMPK increases the activity of the insulin receptor and insulin receptor substrate (IRS) by phosphorylation of these molecules, and then enhances the insulin response and glucose transport ([@b25-ksmcb-42-292])([Fig. 1](#f1-ksmcb-42-292){ref-type="fig"}). AMPK also inhibits fatty acid synthesis by reducing lipogenic gene expression through transcription factors such as sterol regulatory element binding protein-1c (SREBP-1c) carbohydrate-responsive element-binding protein (ChREBP); and enhances β-oxidation by regulating multiple enzymes involved in β-oxidation ([@b79-ksmcb-42-292]; [@b83-ksmcb-42-292]) ([Fig. 1](#f1-ksmcb-42-292){ref-type="fig"}). Metformin has positive effects on metabolism beyond glucose metabolism and also suppresses proinflammatory markers ([@b38-ksmcb-42-292]). Metformin has been reported to suppress lipopolysaccharide (LPS)-stimulated inflammation *via* AMPK-activating transcription factor-3 (ATF-3)([@b41-ksmcb-42-292]). Metformin has also been reported to reduce inflammation through p53-coordinated sestrin2 (SESN2)-AMPK-mTOR signaling in mouse embryonic fibroblasts ([@b17-ksmcb-42-292])([Fig. 2](#f2-ksmcb-42-292){ref-type="fig"}). SESN2 is a target of the tumor suppressor gene p53, and negatively regulates mTOR signaling. Several studies have demonstrated that metformin activates nuclear factor erythroid 2-related factor 2 (Nrf2) in an AMPK-dependent manner, and thereby exerts antioxidant and anti-inflammatory effects under conditions of global cerebral ischemia ([@b2-ksmcb-42-292])([Fig. 2](#f2-ksmcb-42-292){ref-type="fig"}). Metformin can extend lifespan through activation of the liver kinase B (LKB)-AMPK-Nrf2 pathway in *C. elegans* ([@b57-ksmcb-42-292]). Thus, metformin prevents metabolic diseases through AMPK-induced cellular pathways. Metformin has been known to prevent metabolic diseases including diabetes and obesity, and also cancer, through AMPK activation. mTOR induces energy-consuming cellular responses and controls cell growth. Activation of AMPK inhibits the mTOR pathway by phosphorylation of tuberous sclerosis complex (TSC), a tumor suppressor gene ([@b32-ksmcb-42-292])([Fig. 2](#f2-ksmcb-42-292){ref-type="fig"}). AMPK-dependent inhibition of mTOR induces anti-proliferation and inhibits cell viability in several types of cancer ([@b23-ksmcb-42-292]; [@b82-ksmcb-42-292]). Therefore, metformin also protects cancer cell proliferation and growth *via* the AMPK-mTOR pathway.

Several findings support the notion of an AMPK-independent pathway in metabolic diseases. In this context, AMPK-independent effects of metformin have been described. Metformin has been shown to inhibit hepatic gluconeogenesis, which is mediated in an AMPK-independent manner *via* a decrease in hepatic energy state ([@b20-ksmcb-42-292]). In addition, metformin provokes mild mtROS production through inhibition of complex I, and then induces fibroblast growth factor 21 (FGF21) through a mitochondrial stress-induced unfolded protein response (UPR) pathway, known as the endoplasmic reticulum (ER) stress-sensing pathway ([@b42-ksmcb-42-292])([Fig. 2](#f2-ksmcb-42-292){ref-type="fig"}). ROS have been reported to induce the PERK/ eukaryotic initiation factor-2 alpha (eIF2α)/ activation transcription factor-4 (ATF4) pathway, which is one of the three branches of the UPR ([@b50-ksmcb-42-292]). Also, it has been reported that metformin activates the PERK-eIF2α-ATF4 pathway but not the other branches of the UPR represented by activating transcription factor 6 (ATF6) and inositol-requiring transmembrane kinase/endonuclease 1α (IRE1α)([@b65-ksmcb-42-292]). ATF4 prevents obesity and insulin resistance by upregulation of FGF21, an endocrine hormone that exerts effects of anti-obesity and anti-diabetes ([@b43-ksmcb-42-292]). In cancer treatment, metformin exerts anti-cancer effects *via* an AMPK-independent pathway. Metformin, independent of AMPK, exhibits an anticancer effect through the p53-REDD1 (regulated in development and DNA damage responses-1) pathway in a prostate cancer cell line ([@b3-ksmcb-42-292])([Fig. 2](#f2-ksmcb-42-292){ref-type="fig"}). REDD1, known as RTP801, Dig2 and DDIT4, was identified as a hypoxia-inducible factor (HIF)-1 target gene associated with the regulation of cell survival, and negatively regulates mTOR ([@b6-ksmcb-42-292]; [@b70-ksmcb-42-292]). Therefore, REDD1 exhibits an anticancer effect, *via* inhibition of cell growth and cell cycle arrest, through mTOR inhibition. Furthermore, metformin has been shown to inhibit mTORC1, which is mediated in an AMPK-independent manner *via* Rag GTPase inhibition ([@b37-ksmcb-42-292])([Fig. 2](#f2-ksmcb-42-292){ref-type="fig"}). In summary, the ability of metformin to prevent immune-metabolic diseases can be explained by both AMPK-dependent and AMPK-independent mechanisms.

ROLES OF CARBON MONOXIDE IN IMMUNOMETABOLISM
============================================

Cells and tissues have been known to induce an adaptive response to stress ([@b61-ksmcb-42-292]), which is responsible for defending against damage and preserving cellular homeostasis, and depends on the induction of several beneficial defense systems ([@b59-ksmcb-42-292]). Among these, the stress protein HO-1 can defend against cellular damage by the catalysis of heme, a pro-oxidant molecule ([@b59-ksmcb-42-292]). HO-1 can be induced by numerous agents, including CO, curcumin, resveratrol and flavonoids ([@b11-ksmcb-42-292]; [@b53-ksmcb-42-292]; [@b72-ksmcb-42-292]; [@b81-ksmcb-42-292]) ([Fig. 3](#f3-ksmcb-42-292){ref-type="fig"}). The major function of HO-1 is to degrade heme which results in the generation of CO and biliverdin, and the release of iron ([@b61-ksmcb-42-292]). Many reports suggest that the reaction products of HO-1 (i.e., CO, biliverdin and iron) acting individually or in concert, can mediate its cytoprotective effects. In this section, the positive effects of CO are described, with respect to immune responses and metabolism.

CO can exert cytoprotective and therapeutic effects in several disease models ([@b60-ksmcb-42-292]; [@b58-ksmcb-42-292]; [@b55-ksmcb-42-292]; [@b54-ksmcb-42-292]). Also, CO can have a cytoprotective effect at low concentrations ([@b59-ksmcb-42-292]), but may be impractical for clinical use in the gaseous state ([@b33-ksmcb-42-292]). CORMs may be used to exert similar effects as inhalation of gaseous CO in a controlled manner ([@b55-ksmcb-42-292]). CORM compounds, typically transition metal carbonyls that can release CO, include CORM-1, CORM-2, CORM-3 and CORM-A1 ([@b19-ksmcb-42-292]; [@b55-ksmcb-42-292]; [@b56-ksmcb-42-292]) ([Fig. 3](#f3-ksmcb-42-292){ref-type="fig"}). CORM-1 \[Mn~2~(CO)~10~\] was the first of such compounds developed, and is restricted as a pharmacological agent because it is insoluble in aqueous media and requires photoactivation to release CO ([@b55-ksmcb-42-292]). CORM-2 \[Ru(CO~3~Cl~2~)\] is hydrophobic and can release CO from organic solvents ([@b55-ksmcb-42-292]). Further studies have identified water-soluble CORM-3 \[Ru(CO)~3~Cl(glycinate)\] and CORM-A1 \[Na~2~H~3~BCO~2~\]. These CORMs are known to release CO in aqueous media ([@b19-ksmcb-42-292]; [@b56-ksmcb-42-292]). Therefore, these CORMs can potentially treat many disease models by cytoprotective action including antioxidant action. CO has been shown to suppresses the pro-inflammatory response, which is mediated by decreasing the production of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), in the presence of LPS; and by promoting the production of the anti-inflammatory cytokine IL-10, both of which are mediated by activation of the p38 mitogen-activated protein kinase (MAPK) ([@b58-ksmcb-42-292]). Furthermore, CO can generate itaconate, which exerts immunosuppression and anti-microbial functions *via* induction of immune-regulator genes then inhibit pro-inflammatory responses ([@b34-ksmcb-42-292]). CO has been shown to be protective in models of diet-induced obesity, insulin resistance, NAFLD and cancer ([@b30-ksmcb-42-292]; [@b36-ksmcb-42-292]; [@b39-ksmcb-42-292]; [@b40-ksmcb-42-292]). CO and CORM-2 were shown to suppress T cell proliferation through IL-2 production ([@b62-ksmcb-42-292]). CO derived from CORM-A1 inhibited T helper 17 differentiation, which is related to the immunomodulatory effect of CO ([@b73-ksmcb-42-292]). In macrophage polarization, CORM-3 attenuated the expression of iNOS, a marker of M1-polarized macrophage; and upregulated the expression of CD206 and Ym-1 protein, markers of M2-polarized macrophages, in LPS and IL-4-stimulated alveolar macrophages, respectively ([@b80-ksmcb-42-292]). CO induces low levels of mtROS through blocking of mitochondrial ETC complex IV, and subsequently increased mtROS can activate the PERK/eIF2α/ATF4 signaling pathway ([@b50-ksmcb-42-292]; [@b59-ksmcb-42-292]; [@b85-ksmcb-42-292])([Fig. 3](#f3-ksmcb-42-292){ref-type="fig"}). It also has been reported that CO can activate Nrf2, the master regulator of the antioxidant response, *via* PERK activation ([@b8-ksmcb-42-292])([Fig. 3](#f3-ksmcb-42-292){ref-type="fig"}). ATF4 upregulates several genes, FGF21, SESN2 and REDD1, through PERK pathway activation ([@b43-ksmcb-42-292]; [@b39-ksmcb-42-292]; [@b40-ksmcb-42-292]; [@b36-ksmcb-42-292])([Fig. 4](#f4-ksmcb-42-292){ref-type="fig"}). Under high fat diet conditions, CO can increase FGF21 expression by activating the PERK pathway in liver, resulting in metabolic homeostasis through lipolysis of white adipose tissues, conversion from white adipocyte to beige adipocyte, and alleviation of fatty liver ([@b36-ksmcb-42-292])([Fig. 4](#f4-ksmcb-42-292){ref-type="fig"}). Under methionine-choline deficient (MCD) diet conditions, CO has been shown to increase the expression of SESN2 through PERK activation, which activates AMPK which in turn inhibits mTOR signaling to induce autophagy, resulting in the amelioration of MCD-induced steatohepatitis ([@b39-ksmcb-42-292])([Fig. 4](#f4-ksmcb-42-292){ref-type="fig"}). CO induces REDD1 through PERK activation, and subsequently, REDD1 can inhibit cell cycle arrest, growth and metastasis of tumors by inducing mTOR inactivation and apoptosis ([@b40-ksmcb-42-292])([Fig. 4](#f4-ksmcb-42-292){ref-type="fig"}). Therefore, CO has been shown to prevent diet-induced obesity, insulin resistance and NAFLD *via* FGF21 and SESN2; and to prevent tumor growth and metastasis *via* REDD1. Thus, CO-induced protective effects in metabolic diseases can occur in a PERK-dependent manner.

SIMILARITIES OF METFORMIN AND CARBON MONOXIDE
=============================================

Metformin and CO generate ROS through blocking of mitochondria ETC. The generated-ROS activate PERK/eIF2α/ATF4 signaling, one of the branches of the UPR, but not IRE1α and ATF6. Metformin and CO both increase the expression levels of FGF21, SESN2 and REDD1, and also activate Nrf2. Specifically, FGF21 was induced by metformin and CO *via* PERK-activated ATF4. Therefore, metformin and CO exert positive effects in metabolic diseases, such as obesity, insulin resistance, NAFLD and cancer, through the regulation of the metabolic homeostasis molecules, FGF21, SESN2, REDD1 and Nrf2 ([Table 1](#t1-ksmcb-42-292){ref-type="table"}).

DISTINCTIONS OF METFORMIN AND CARBON MONOXIDE
=============================================

Metformin induces ROS *via* inhibition of mitochondria ETC complex I. The elevation in ROS increases the level of AMP, leading to activation of AMPK. The increased AMPK activation enhances insulin sensitivity through improved glucose transport and activity of the insulin receptor and IRS, and regulates fatty acid synthesis and β-oxidation, and subsequently these responses exert effects on metabolic homeostasis. In contrast, CO can produce mtROS through blocking of mitochondrial ETC complex IV, leading to activation of PERK signaling by mtROS. CO reversed insulin resistance and obesity *via* the PERK/eIF2α/ATF4-induced FGF21. FGF21 enhanced by CO stimulated the exhibition of insulin sensitivity and the transition of brown adipose tissues (BAT) from white adipose tissues (WAT). Furthermore, CO induces SESN2 *via* ATF4 and attenuates MCD induced-hepatitis through SESN2-induced AMPK and autophagy.

Metformin increases activity of Nrf2 in an AMPK-dependent manner and then exerts anti-oxidant and anti-inflammatory effects. Also, metformin increases lifespan through AMPK-activated Nrf2 signaling. While metformin activates Nrf2 *via* AMPK, CO enhances Nrf2 nuclear translocation by PERK activation. Nrf2 in turn upregulates HO-1 and then exhibits therapeutic effects in vascular diseases. Metformin inhibits proliferation of cancer cells through AMPK-dependent mTOR inhibition and AMPK-independent transcriptional regulation of REDD1 through p53. In contrast, CO upregulates REDD1 *via* PERK-dependent ATF4 which inhibits the proliferation of cancer cells ([Table 1](#t1-ksmcb-42-292){ref-type="table"}).

CONCLUSIONS
===========

As we have discussed, both metformin and CO can attenuate metabolic diseases, such as obesity, type 2 diabetes (DM2), NAFLD and cancer through similar responses, involving induction of mild ROS-enhanced metabolic homeostasis molecules. While numerous studies have shown that metformin is associated with activation of AMPK and p53 in the induction of metabolic effector molecules, the effects of CO are related to the PERK-dependent ATF4 pathway. However, more research is needed to understand the detailed pathways by which metformin and CO impact immunometabolism.
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![Metformin inhibits mitochondrial complex I and activates AMPK *via* decreasing ATP levels, thereby increasing glycolysis and lipolysis and inhibiting gluconeogenesis and lipogenesis. Metformin also increases glucose translocation and improves insulin sensitivity. *See* the text for more details.](ksmcb-42-292f1){#f1-ksmcb-42-292}

![Metformin acts through both AMPK-dependent and AMPK-independent pathways to control the survival of cells and metabolic homeostasis. *See* the text for more details.](ksmcb-42-292f2){#f2-ksmcb-42-292}

![Carbon monoxide inhibits mitochondrial complex IV and then activates PERK via increasing mitochondrial ROS. Activated PERK induces the Nrf2-HO-1 pathways. HO-1 is induced by the various stimulators such as CO, curcumin, resveratrol and flavonoids, thereby increasing endogenous CO production. And also, CO-releasing molecules (CORM-1, 2, 3, and A1) produce CO in cells. See the text for more details.](ksmcb-42-292f3){#f3-ksmcb-42-292}

![Carbon monoxide controls metabolic homeostasis via the PERK-eIF2α-ATF4-FGF21, SENS2, and REDD1 pathway. See the text for more details.](ksmcb-42-292f4){#f4-ksmcb-42-292}

###### 

Similarities and distinctions of metformin and carbon monoxide

                                                                                                                                                                                                                                                                    Metformin                                                                                                                                                   Carbon monoxide
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------
  Similarity                                                                                                                                                                                                                                                        \- Exhibiting effects of cytoprotection by production of ROS in mitochondria ([@b42-ksmcb-42-292]; [@b50-ksmcb-42-292]; [@b85-ksmcb-42-292])                
  \- Activation of the PERK pathway by induction of mitochondrial stress ([@b36-ksmcb-42-292]; [@b42-ksmcb-42-292]; [@b39-ksmcb-42-292]; [@b65-ksmcb-42-292])                                                                                                                                                                                                                                                                   
  \- Induction of metabolic homeostasis molecules (e.g., FGF21 and SESN2) and anti-tumor and anti-oxidant molecules (e.g., REDD1 and Nrf2, respectively) ([@b3-ksmcb-42-292]; [@b17-ksmcb-42-292]; [@b44-ksmcb-42-292]; [@b42-ksmcb-42-292]; [@b40-ksmcb-42-292])                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                
  Distinction                                                                                                                                                                                                                                                       \- Increase of ROS by partial inhibition of mitochondrial complex I ([@b42-ksmcb-42-292]                                                                    \- Production of ROS via temporarily blocking cytochrome c oxidase, complex IV ([@b59-ksmcb-42-292]; [@b85-ksmcb-42-292])
  \- Induction of SESN2 and REDD1 by the p53-dependent pathway in mouse embryonic fibroblasts and prostate cancer cell lines, respectively ([@b3-ksmcb-42-292]; [@b17-ksmcb-42-292])                                                                                \- Induction of SESN2 and REDD1 by PERK-dependent pathway in liver and several cancer cell lines, respectively ([@b39-ksmcb-42-292]; [@b40-ksmcb-42-292])   
  \- Activation of Nrf2 in an AMPK-dependent manner in rat brain and *C. elegans* ([@b2-ksmcb-42-292]; [@b57-ksmcb-42-292])                                                                                                                                         \- Activation of Nrf2 via PERK activation in human endothelial cells ([@b44-ksmcb-42-292])                                                                  
